ChemGenex submits leukemia drug for FDA review

ChemGenex Pharmaceuticals filed for FDA approval of omacetaxine, a drug candidate for chronic myeloid leukemia. The Australian biotech firm hopes to market the small molecule therapy under the brand Omapro in the first half of next year.

View Full Article in:

Herald Sun (Melbourne, Australia) (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC